Direct Analysis of Pharmaceutical Drug
Formulations Using Ion Mobility Spectrometry/Quadrupole-Time-of-Flight Mass Spectrometry
Combined with Desorption Electrospray Ionization
posted on 2005-12-01, 00:00authored byDaniel J. Weston, Robert Bateman, Ian D. Wilson, Tim R. Wood, Colin S. Creaser
A novel approach to the rapid analysis of pharmaceutical
drug formulations using hyphenated ion mobility spectrometry (IMS) and time-of-flight mass spectrometry (ToF-MS) that requires no sample pretreatment or chromatographic separation is described. A modified quadrupole
time-of-flight mass spectrometer containing an ion mobility drift cell was used for gas-phase electrophoretic
separation of ions prior to ToF-MS detection. The generation of sample ions directly from tablets and cream
formulations was effected by desorption electrospray
ionization (DESI) using a modified electrospray ion source.
The analysis of a range of over-the-counter and prescription tablet formulations is described, including histamine
H2 receptor antagonist (ranitidine), analgesic (paracetamol), opiate (codeine), and aromatase inhibitor anticancer
(anastrozole) drugs. The successful determination of
active drugs from soft formulations, such as an antiseptic
cream (chlorhexidine) and a nicotine-containing skin
patch, is also presented. Limits of detection for the active
drugs using the DESI/IMS/ToF-MS method fell within the
high-picomole to nanomole range. In all cases, the use of
ion mobility drift tube separation showed increased
selectivity for active drug responses (present as low as
0.14% w/w) over excipient responses such as poly(ethylene glycol). Tandem mass spectrometric analysis of
precursor ions separated by IMS allowed positive confirmation of active drugs with little loss of ion mobility
efficiency. The ability to analyze hard or soft pharmaceutical formulations directly by DESI combined with ion
mobility spectrometry/mass spectrometry in ∼2 min
demonstrates the potential applicability of this novel
method to pharmaceutical screening of low-molecular-weight drug formulations with high selectivity over the
formulation vehicle.